We demonstrate activation of primary human TCRBV-specific CD4
Introduction
Antigen recognition by the T cell receptor (TCR) is thought to involve its complementarity determining region 3 (CDR3), which serves as the point of contact between the T cell and the peptide antigen presented by the host major histocompatibility complex (MHC) molecule. The CDR3, located at the junction of the variable (TCRBV), diversity (TCRBD) and junctional (TCRBJ) segments of the TCR␤ gene, is highly variable in structure and is associated with specific antigen recognition. 1 Since a major outcome of this recognition is clonal expansion of the responding T cells, investigators have sought to utilize specific T cell oligoclonality in various clinical conditions as a measure of T cell activation in vivo. [2] [3] [4] This approach has inherent limitations with often rather conflicting results 5 due to the occurrence of pre-existing expanded CD8 +
CD45RO
+ T cell clones in the circulation. 6 The cause(s) of the CD8 + T cell clonality observed by this approach continue(s) to remain obscure. 7 Pre-existing clonal TCR expansions are uncommon in the CD4
+ T cell subset. 3, 8 This difference between the CD4 + and CD8 + T cell subsets is probably a reflection of their different activation requirements. 9 In contrast to CD8 + T cells, demonstration of a CD4 + clonal response to nominal antigen in primary peripheral blood mononuclear cells (PBMC) in vitro has so far been experimentally elusive. 10 A few studies utilizing CD4 + T cell clones have shown restricted responses to antigen in vitro in humans 11, 12 and in mice. 7 However, results from experiments conducted with cell clones require caution in interpretation, as manipulated cell conditions may not reflect the natural situation.
In view of the central role of CD4 + T cells in the immune response, we devised a reproducible method to observe clonal antigenic activation in vitro of human CD4 + T cells bearing specific TCRBV families. To determine that the clonal expansion was antigen-specific, we stimulated cells with two distinct recall antigens. Our results showed that both HBsAg and TT induce expansion of unique and specific monoclonal or oligoclonal nucleotide and amino acid sequences in the CDR3 region of TCRBV16 in CD4 + PBMC of immunized donors.
Results

CD4
+
CD45RO
+ cells increase in number following coculture with HBsAg Activation of CD4 + PBMC with HBsAg was carried out over 21 days, while activation with TT was for 14 days. To test whether the cells responded to antigen stimulation, a sample of the co-cultured cells was examined on day 7 by antibody staining and flow cytometric analysis. 13 Approximately 71% of cells in co-culture with HBsAg were CD4 + , over 80% (58%/71%) of which were CD45RA − ( Figure 1c ). These CD4 + CD45RA − cells showed a bimodal distribution of cell surface CD4. In contrast, CD4
+ PBMC incubated without HBsAg showed a uniform distribution of CD4 (Figure 1a ). The majority of the HBsAg-treated CD4 +
CD45RA
− PBMC were CD45RO + ( Figure 1d ). CD45RO + PBMC increased two-fold in the presence of HBsAg over cells cultured without HBsAg (Figure 1c) . This difference correlated with increased cell surface density of CD4. The mean fluorescence intensity of anti-CD4-PE increased to 253% in the cells cultured in the presence of HBsAg compared to 161% in the control cells (relative to values obtained prior to co-culture at the start of the experiment; data not shown). This result is representative of triplicate (SMA and ELE) or quadruplicate (MEC and RBA) experiments for both HBsAg and TT presentations in all four study subjects. Moreover, the
Figure 1 Phenotype characteristic of CD4
+ PBMC activated by HBsAg. CD4 + PBMC co-cultured with or without HBsAg were stained with anti-CD45RA or anti-CD45RO antibodies to determine surface membrane phenotype after 7 days in culture. CD45RO
+ cells increased twofold among cells co-cultured with HBsAg (d) over cells cultured in the absence of antigen (b). In contrast, CD45RA
+ cell number was similar in those co-cultured with (c) or without (a) HBsAg. results were in essence similar whether performed on day 7 or on day 14 in each case.
Clonal TCRBV expansion is limited to CD45RO
+ cells To determine whether clonally expanded TCRBV message was preferentially found in a particular CD4 + T cell subset after antigen co-culture, the co-cultured cells were separated into CD45RA + and CD45RO + subsets. PBMC from donor ELE showed clonal expansion within TCRBV9 (Figure 2a 
Clonal expansion within several TCRBV families following CD4
+ cell stimulation with antigen Several TCRBV families showed apparently oligoclonal expansion following incubation with HBsAg or TT. Some TCRBV families were more commonly used than others. Overall, there was limited TCRBV gene family usage in response to either HBsAg or TT. However, the band intensity was not always the same in all responding TCRBV families. In some cases, two or more clonal bands Genes and Immunity were observed within the same BV family in response to antigenic activation (data not shown). Unrelated individuals often used the same TCRBV gene family in response to HBsAg or TT activation (Table 1) . For instance, TCRBV16 was utilized by SMA, MEC and RBA in response to HBsAg. Similarly, SMA, ELE and MEC utilized TCRBV17 in response to TT (Table 1) . In almost every case of TCRBV gene family sharing, however, the expanded band sizes in the spectratypes were different among the subjects (data not shown).
A dominant band (by visual examination) was considered oligoclonal if, after analysis by computerized densitometry to determine its density relative to other bands in the spectratype of a particular TCRBV family, the band met one of two criteria. The first criterion was that the density of the band comprised Ͼ50% of the whole family's spectratype, as previously suggested. 8 An alternative criterion was to include bands which appeared de novo in the spectratype of the antigen-stimulated cell population but were apparently missing in the untreated control cell population. More generally, a spectratype band in the antigen-treated sample with an intensity estimated to be at least twice that of a counterpart control band and causing a distortion in the Gaussian distribution of band intensity seen in the untreated sample was considered worthy of further study.
HBsAg activation of TCRBV16 is monoclonal and oligoclonal
Two of the three CD4
+ PBMC that utilized BV16 in response to HBsAg, SMA and RBA (Figure 3a and e), showed dominant bands (Ͼ50% intensity of the entire spectratype) and were more intense than juxtaposed bands in the control CD4 + PBMC incubated in the absence of HBsAg. The third sample reactive to HBsAg and utilizing TCRBV16 (MEC) was less intense in its dominant band (approximately 30%) but was included because this band appeared de novo in the spectratype of activated cells ( Figure 3c , lane 2) but not in the control cell-derived spectratype ( Figure 3c , lane 1). The distribution of band intensities from the control samples was always Gaussian, whereas the spectratypes from HBsAgtreated cells which had oligoclonal TCRBV16 bands always showed skewed distributions of band intensity (Figures 3b, d and f).
Our interest in TCRBV16 was informed by the fact that it was the most commonly used family by our donors in response to HBsAg. In addition, one of these donors (SMA), used TCRBV16 in the response to both HBsAg and to TT. We therefore reasoned that determination of the CDR3 sequences of TCRBV16 bands induced by the two nominal antigens was important in testing the specificity of our observations. Accordingly, the cDNA in all TCRBV16 bands with suspected clonality to antigen were cloned and sequenced. Sequences obtained from all the clones were in-frame within the CDR3 region. The sequences began 33 amino acids upstream of the conserved BV sequence cysteine-alanine-serine (C-A-S), and included the BD region and the entire BJ segment including the conserved phenylalanine-glycine-x-glycine (F-G-X-G) sequence.
Fourteen out of 17 (82%) randomly picked clones with cDNA inserts derived from the SMA-TCRBV16 band in response to HBsAg yielded the same nucleotide sequence ( Figure 4 , sequence SMA (HBsAg)). The remaining three sequenced clones (18%) were all different (not shown). The three different sequences may represent background (non-HBsAg-specific) sequences. The TCRBV16 response by SMA to HBsAg was therefore essentially monoclonal superimposed on a background polyclonal band. Translation of the dominant nucleotide sequence into protein showed that the TCRBV16 response to HBsAg in SMA utilized a CDR3 length of 10 amino acids. The BD1*01 and BJ2-5 elements were used (Table 2) . Two nucleotides were added 5Ј to the BD element and three nucleotides were added 3Ј of the BD region but 5Ј to the BJ segment. This resulted in a total of five non-germline nucleotides added as part of the N-(D)-N region. An exonucleolytic nibbling event 14 may also have occurred which removed one cytosine-and four guanine-containing residues at the 3Ј end of the BD segment of the CDR3.
Twenty randomly-picked plasmid clones from the HBsAg-stimulated MEC sample were sequenced. All the clones (100%) yielded a single nucleotide sequence ( Figure 4 , sequence MEC (HBsAg)). Thus, the TCRBV16 response to HBsAg in MEC was monoclonal. The CDR3 region was 14 amino acids in length, which was four residues longer than in SMA. Further, the TCRBV16 response to HBsAg in MEC utilized the BD2 and BJ2-7 elements in the joining region. There was no nucleotide addition between the D and J elements, but 19 nucleotides were Genes and Immunity added between the BV and BD segments. One adenineand three guanine-containing residues were nibbled at the 5Ј end, while seven or eight other nucleotides were nibbled at the 3Ј end of the BD element. The cytosinecontaining residue at the 5Ј end of the BJ region may have been nibbled. Alternatively, the cytosine was nibbled from the BD element.
Analysis of plasmid clone sequences from sample RBA showed that the TCRBV response was oligoclonal. Of 17 nucleotide sequences analyzed in RBA, 10 (59%) were identical ( Figure 4 , sequence RBA (HBsAg)). Three additional sequences, one with 29% frequency and the remaining two with 12% each, were also observed in clones from sample RBA (not shown). The dominant sequence had a CDR3 length of 11 amino acids. Similar to MEC, the dominant clone in RBA utilized the BJ allele 2-7. The BD region element could not be assigned using previously given 14 criteria (Figure 4 ). There were 18, 21 or 24 non-germline nucleotides added overall in this sequence.
cDNA bands from the untreated cells matching the position of the HBsAg-treated dominant bands were also cloned and sequenced as a control to determine the frequency of the HBsAg-specific TCRBV16 sequence in the unstimulated CD4
+ PBMC. Analysis of 16 clones of the control band in SMA showed 15 different sequences with various CDR3 lengths, but none of these clones was identical in nucleotide or protein sequence to the HBsAgspecific oligoclonal sequence observed in cDNA from the antigen-stimulated cells. Interestingly, one out of 15 clones from the control cDNA in sample RBA contained an identical nucleotide sequence to the dominant oligoclonal sequence in the antigen-treated sample. The remaining 14 sequences were different from each other and comprised various CDR3 lengths. Sample MEC, which had a monoclonal TCRBV-CDR3 response to HBsAg, lacked a control band at the dominant band position and therefore could not be tested for frequency of the HBsAg-specific response sequence in the untreated cells.
Antigenic activation of CD4 + T cells is reproducible and stable
We showed, as demonstrated in Figure 2 , that the apparently clonal response to TT was reproducible in separate experiments and that similar-sized bands were expanded in response to TT by CD4 + T cells obtained 10 months apart. To test the reproducibility and stability of the CDR3 sequences, cDNA from the seemingly clonal bands observed within the TCRBV16 family using the CD45RO + cells were further cloned and sequenced. Analysis of 23 plasmid clones from the two separate experiments involving the same donor (11 clones of one and 12 clones of the other) showed that these bands were oligoclonal in that nine of 11 clones from experiment 1 and nine of 12 clones from experiment 2 had identical nucleotide and amino acid sequences within each experiment. These sequences were also identical across the two experiments. Thus, a total of 18 of 23 clones (82%) were identical in nucleotide and derived amino acid sequences in the CDR3 region of TCRBV16 in the response to TT by subject ELE from samples obtained 10 months apart (Table  2 and Figure 4) .
In vitro CD4
+ -TCRBV activation GP Uko et al Amino acids encoded in the CDR3 region (shown in bold) varied in length between subject samples or antigen used in stimulation. Nucleotide addition in the N-D-N region or nibbling within CDR3 also varied in the same order.
The TCRBV16 monoclonal response to TT is distinct from the response to HBsAg
The CDR3 sequence specificity of the TCRBV16 response to HBsAg in SMA was tested by also cloning and sequencing the cDNA from the dominant TT-specific band. Interestingly, the nucleotide sequence analyzed was the same in eight out of eight clones from the TCRBV response to TT (Figure 4 , sequence SMA (TT)). In contrast to the SMA response to HBsAg, the CDR3 region length in response to TT comprised 11 amino acids. Whereas the response by SMA to HBsAg utilized the BD1*01 and BJ2-5 alleles, the response to TT utilized BD2 and BJ2-3 elements. Further differences between the two antigenstimulated responses were observed in the type, number and location of nucleotide additions in the N-(D)-N region. The response to TT was characterized by five nucleotides added between the V and D segments and only one nucleotide addition between the D and J segments (Table 2 ). In addition, exonucleolytic nibbling events in the BD region resulted in loss of three guaninecontaining residues upstream and an additional seven residues composed of either guanine alone or one adenine-and six guanine-containing residues downstream, preceding the BJ segment. The CDR3 sequences generated in response to TT by SMA and ELE were also compared and showed some degree of similarity as well as differences. Both responders showed four identical nucleotides added in the N-D-N region. This addition resulted in the coding for glutamine immediately next to serine at the commencement of the CDR3 region in both responders. (However, this insertion was not unique to the TT response; see the HBsAg response in MEC and RBA.) The response to TT in these two subjects also used similar BD elements but different BJ elements (Table 2, Figure 4 ). There was only one nucleotide inserted between the BD and BJ regions of the CDR3 in the TT response by SMA, whereas five nucleotides were inserted within the same region in the TT response by ELE. Moreover, the BJ element in the CDR3 response by SMA to TT remained intact, whereas exonucleolytic nibbling was evident in the BJ region of the CDR3 response by ELE. This nibbling resulted in the loss of seven nucleotides. The CDR3 length used in response to TT by SMA was longer (11 amino acids) than that (10 amino acids) used for the TT response by ELE.
Discussion
We have demonstrated that CD4 + T cells from immunized donors respond to HBsAg or TT in vitro in the absence of added cytokines, with a resultant donorspecific and antigen-specific TCRBV expansion. Within a given TCRBV family, this response is oligoclonal or monoclonal. Our approach relies on the repeated exposure of the selected cell population to antigen over several cycles of stimulation. We adopted appropriate quality control measures in the experimental procedures, and we showed that the induced proliferation of the CD4 + T cells was specific, stable over time, reproducible and correlated with expansion of specific TCRBV families attributable to only the CD4 +
CD45RO
+ T cell phenotype. The monoclonal or oligoclonal TCRBV-CDR3 responses we observed cannot be due to superantigen contamination of our experimental system because the responses were not polyclonal, whereas TCRBV family expansion in superantigen responses is polyclonal. 15 Second, the reproducibility and specificity of our observations, which were only in a few TCRBV families, exclude experimental artifacts due to antigen, media or cells. PBMC from these donors were found to proliferate specifically to HBsAg, since PBMC from nonresponders and naive subjects did not proliferate. 16 Our method is therefore capable of detecting, for the first time, recall antigen-specific monoclonal or oligoclonal TCRBV sequences in primary CD4 + PBMC without resort to the use of IL-2 for cell line expansion.
Previous attempts to study the T cell receptor specificity of CD4 + T cells in response to recall antigen stimulation were frustrated by the lack of an appropriate in vitro experimental system. Researchers resorted to determining the TCRBV usage ex vivo after a course of appropriate immunizations. 6 The results were not satisfactory in that evidence of T cell activation was found only in the CD8 + T cell subset but not the CD4 + subset. It was, moreover, not clear that activation of the CD8 + T cells was antigen-induced because CD8 + T cells from healthy unvaccinated individuals sometimes show mono-clonal bands without identifiable antigenic exposure. 8 Similarly, others 17 failed to identify any specific TCRBV family utilized by CD4 + T cells in response to HBsAg immunization. Specific clonal expansion of T cells using their approach would be almost impossible to demonstrate, since an entire TCRBV family does not expand following activation, particularly if the response to HBsAg vaccine only partially mimics the polyclonal T cell response observed in an acute infection by the live virus. 18 Instead, as we have demonstrated, only a band or two within the TCRBV family spectratype may be expanded. On the other extreme, another report 11 showed restricted TCRBV length expansion within many different TCRBV families in cell lines from two HBsAg-vaccinated donors. The cell lines were generated by repeated stimulation of donor PBMC with HBsAg and with the addition of IL-2. The cells were not characterized in terms of CD4
+ or CD8 + cell subsets. More recently, however, an assay thought to be sensitive for detecting CD4
+ T cell expansion due to a recall antigen in vitro was reported 19 but the clonality of the suspected expansion was not shown.
Although we found oligoclonality or monoclonality within a single expanded band of a given TCRBV family, we also found that the TCR response to either HBsAg or TT resulted in an apparently oligoclonal expansion within several TCRBV families for every subject tested. The number of TCRBV families expanded, however, was far fewer than previously reported, 11 perhaps because we limited our study to the CD4 + response or because IL-2 was not added. We make these deductions based on our experience that CD4 + and CD8 + PBMC utilize different TCRBV families in response to the same antigenic stimulus (unpublished observations). Co-culture of mixed PBMC, unselected for T cell subsets, with antigen might therefore result in expansion of multiple TCRBV families. Moreover, IL-2 generates nonspecific and sometimes transient TCRBV family responses in T cell lines or clones. 12 The stability of the TCRBV repertoire per se in response to recall antigen is currently unknown. However, in the present study the response to TT using TCRBV16 was stable over at least 10 months in the subject tested. Studies to determine the actual evolution and general stability of a given TCRBV repertoire following immunization need to be performed. Also important is the nature of the T cell receptor alpha variable (TCRAV) domain response to HBsAg. This domain is critical in thymic development of the T cell as well as in the activation of mature T cells. 20 However, these exciting areas are beyond the scope of our present report.
We found that the intensity of band expansion following T cell activation does not have a simple direct relationship with oligoclonality or monoclonality. For example, the two bands which showed oligoclonal expansion by our sequence data had Ͼ50% band intensity, whereas a monoclonal nucleotide sequence was obtained from clones of a third band which had only 30% band intensity. Therefore, proper assignment of clonality to a particular TCRBV family requires that the dominant band be identified, isolated and sequenced separately. Although we essentially always found only a single band expanded in any given TCRBV family, we never found a whole TCRBV family response restricted to a single band length, in contrast to previous reports.
6,11 However, we
Genes and Immunity found that clonal bands were observed only in CD45RO + -enriched T cells. This observation was first reported in CD8 + T cells examined ex vivo, 6 and our results suggest that rapidly expanding CD4 + T cells responding to antigen are only CD45RO + . Our approach should allow us to study the nonresponse to HBsAg vaccination in humans, which is thought to be associated with a defect in the T cells. 21, 22 It is clear from our data that, for a given individual, CD4 + T cells bearing TCR of several TCRBV families expand following stimulation with HBsAg. Identification of commonly utilized TCRBV sequences (or motifs) from monoclonal and oligoclonal responses, especially in the most variable regions within the CDR3, may be useful for identifying whether nonresponder CD4 + T cells carry or do not carry those sequences. This application has been recently demonstrated in a disease study. 23 Motif study will help to distinguish anergy from a hole in the repertoire as the basis for nonresponsiveness to HBsAg vaccine. However, since HBsAg-specific responses in cells not stimulated with HBsAg in vitro are rare, a very sensitive detection system will be required to investigate the T cell repertoire of nonresponders.
Our current data are insufficient to determine the mechanism for nonresponse to HBsAg. Subjects responding to HBsAg vaccine utilize both common and different TCRBV families in this response as well as different CDR3 lengths within shared activated families. The differences in CDR3 lengths used by the three study subjects could be caused by responses to different processed epitopes. We may have to simplify the system by using only one or a few immunogenic peptides 18 to address specific questions such as the genetic (including MHC) control of particular CDR3 usage or the TCR response to a single epitope. The major predictor of the utilized CDR3 length and sequence might also be the MHC, which is thought to shape the TCR repertoire. 24 In our present report, only two out of three subjects whose CDR3 lengths for HBsAg were sequenced were also typed for MHC antigens. Those two differed in terms of their MHC phenotypes (data not shown). It may be necessary to study the TCR CDR3 motifs solely in known responders with MHC extended haplotypes known to confer susceptibility to nonresponse. 25 These experiments are underway in our laboratory. In any case, a precise understanding of the human TCRBV response to HBsAg will rely on the use of peptide sequences that activate specific but common motifs in the human TCRBV repertoire.
Materials and methods
Study subjects and vaccination
Four known responders to HBsAg vaccine were recruited for the study with informed consent. These subjects had previously received a full course of intramuscular (deltoid) immunization with Recombivax Hepatitis B (a gift from Dr David J West, Merck & Co; West Point, PA, USA) and had specific antibody titers Ͼ10 IU/L 5 week post-immunization. The subjects were given a further vaccine booster, and blood was collected 5 weeks later. The subjects had also previously received a full course of TT vaccination with boosters. 16 They were bled for this study at different times, ranging from 1-10 year post boost.
CD4
+ PBMC isolation PBMC were obtained by centrifugation over Ficoll (Pharmacia, Piscataway, NJ, USA) from heparinized whole blood. CD4
+ cells were enriched from total PBMC by negative selection using monoclonal anti-CD8 + -coated microbeads on MACS separation columns according to the manufacturer's specifications (Miltenyi Biotec, Auburn, CA, USA). In order to minimize nonspecific monoclonal antibody binding, the cells were initially treated with blocking buffer containing 20 mg/ml human IgG. 13 
CD8
+ T cells present in the enriched CD4 + T cell population were always Ͻ5% of total T cells (data not shown).
Monoclonal antibodies and flow cytometry
Mouse monoclonal antibodies against CD4 (phycoerytherin-13B8.2), CD8 (phycoerythrin-cyanin 5.1-B9.11), CD45RA (fluorescein isothiocyanate (FITC)-ALB11) and CD45RO (FITC-UCHL1) and their mouse isotype-matched immunoglobulin controls were obtained from BeckmanCoulter (Somerset, NJ, USA). Cells (at 1 × 10 6 cells/ml) were stained in PBS containing 10% heat-inactivated pooled human serum to block nonspecific binding for 30 min at 4°C followed by three washes with PBS, and fixed in 1% paraformaldehyde prior to analysis on an EPICS XL-MCL flow cytometer (Coulter, Hialeah, FL, USA) using EXPO XL4 cytometric software. Data from 10 000 events were collected, and standard unstained, isotypestained and positively-stained controls were used to set forward and side scatter gating as well as fluorescence gating for each of the three colors.
Antigen presentation CD4
+ -enriched PBMC were suspended at a concentration of 1 × 10 6 cells/ml in culture medium containing RPMI 1640 (Cellgro) supplemented with 10% heat-inactivated pooled human serum (Nabi, Boca Raton, FL, USA), 2 mM L-glutamine, 100 g/ml streptomycin and 100 U/ml penicillin (Life Technologies, Gaithersburg, MD, USA). Recombinant HBsAg (a kind gift of Dr Alan R Shaw, Merck Research Laboratories, West Point, PA, USA) or TT (Connaught Laboratories, Willowdale, ON, Canada) was added to the culture medium-PBMC mixture to a final concentration of 1 g/ml. The cell mixture (200 l) was dispensed into each well of a 96-well culture plate and incubated at 37°C in a 5% CO 2 humidified environment. Cells in culture medium lacking antigen served as the unactivated control.
The cells were supplemented with fresh medium on day 4, and on day 7 the supplement comprised 5 × 10 4 autologous antigen presenting cells (APC) per well as well as the antigen being presented as above. The cycle of renewed media, APC and antigen was conducted once for TT and twice for HBsAg for a final incubation period of 14 or 21 days, respectively. The cells were harvested for CD45 selection at the end of the incubation period.
Isolation of CD45RA/RO-bearing cells CD4
+ -enriched cells expressing CD45RA or CD45RO were isolated after culture using a selection method on MACS separation columns with immunomagnetic microbeads coated with anti-CD45RA antibody according to the manufacturer's specifications as described above. Thus, the CD45RA + cells were positively selected and the CD45RO + cells were collected as the unbound fraction from the column. mRNA isolation and first strand cDNA synthesis Messenger RNA was isolated from cells using the RNeasy mini kit (Qiagen, Valencia, CA, USA). The total RNA (usually about 1-5 g) was used in first strand cDNA synthesis in reverse transcriptase-polymerase chain reaction (RT-PCR) using the Superscript Preamplification kit with oligo(dT) [12] [13] [14] [15] [16] [17] [18] as the primer (Life Technologies).
5Ј end-labeling and purification of reverse primer
The reverse primer used in amplification of the cDNA from the cultured cells was end-labeled with 32 P(␥-ATP) (DuPont NEN, Boston, MA, USA) in a reaction catalyzed by T4 polynucleotide kinase (Life Technologies). The labeled primer was purified using nucTrap probe purification columns (Stratagene, Cedar Creek, TX, USA). PCR was performed using the multiplex primer method for amplification of TCRBV genes and primer sequences as previously published. 8 Briefly, PCR was performed in a 25 l volume reaction mixture containing 1.5 g template cDNA, 6 pM unlabeled reverse primer, 1.25 pM labeled reverse primer, 1 pM multiplex forward primer, 2.5 mM MgCl 2 in 10× PCR buffer (Perkin Elmer, Branchburg, NJ, USA), 0.5 mM dNTP (Life Technologies) and 0.6 U of Amplitaq (Perkin Elmer) in DEPC-treated water (Life Technologies). DNA amplification was performed in 35 cycles of denaturing at 95°C for 1 min, annealing at 60°C for 30 s and extension at 72°C for 1 min.
Spectratyping
The amplified cDNA (8 l) was loaded on an 8% polyacrylamide sequencing gel containing 40% (19:1) acrylamide:bisacrylamide solution (National Diagnostics, Atlanta, GA, USA) under denaturing conditions with ultrapure urea (ICN Biochemicals, Costa Mesa, CA, USA) and electrophoresed at 75 W over 3 h. The finished gel was dried and exposed to a phosphorscreen prior to examination for TCRBV-CDR3 bands on a Storm scanner (Molecular Dynamics, Sunnyvale, CA, USA). Analysis of bands for apparent oligoclonality by band intensity was performed with ImageQuant software (Molecular Dynamics).
Cloning and sequencing
An apparently clonal band as determined by densitometric analysis was cut out from the gel, and the DNA was eluted using the QIAquick protocol (Qiagen). The purified DNA was amplified with its specific TCRBV forward primer in order to generate a sharp-ended PCR product as described above, except that the reverse primer was not labeled. The cDNA was inserted into the EcoR I site of the pCR4-Topo plasmid vector (Invitrogen, Carlsbad, CA, USA). The transfected E. coli clones were selected by kanamycin resistance. The plasmids were purified using SNAP purification columns (Invitrogen) and sequenced on the OpenGene automated DNA sequencing system (Visible Genetics, Toronto, ON, Canada) using Cy5/Cy5.5 dye primer which contains M13 universal primer in the sequencing protocol or using the automated High Throughput DNA sequencing facility of Harvard Medical School (Boston, MA, USA).
